NCT05587361View on ClinicalTrials.gov

Beta-Adrenergic Modulation of Drug Cue Reactivity

PHASE4RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 26, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

March 1, 2026

Conditions
Tobacco Use DisorderNicotine DependenceCigarette Smoking
Interventions
DRUG

Propranolol

Propranolol Capsule; 40 mg IR

DRUG

Nicotine Patch

Nicotine Patch; 14 mg

DRUG

Placebo Propranolol

Placebo Capsule, no active ingredients

DRUG

Placebo Patch

Placebo Patch, no active ingredients

Trial Locations (1)

74136

RECRUITING

Hardesty Center for Clinical Research and Neuroscience, Tulsa

Sponsors

Collaborators (1)

Duke University
All Listed Sponsors
collaborator

Oklahoma State University Center for Health Sciences

OTHER

collaborator

Duke University

OTHER

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

University of Oklahoma

OTHER